Dr. Mini Michael, M.D.
Pediatric Nephrology (Pediatric Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 15
Licensed in Texas since 2004, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Nephrology Physician primary
TX license L8134 (first issued 2004; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Texas Childrens Hospital Houston, TX
Medical groups
- Texas Childrens Physician Group (671 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 15
- Services billed
- 54
- Patients’ average age
- 12
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 10 payments worth $20,216 in total to this clinician.
| Alnylam Pharmaceuticals Inc. | $16,992 |
|---|---|
| Novo Nordisk Inc | $3,098 |
| Apellis Pharmaceuticals, Inc. | $126 |
| Compensation for services other than consulting (speaking, faculty) | $10,990 |
|---|---|
| Travel and Lodging | $5,894 |
| Consulting Fee | $2,998 |
| Food and Beverage | $270 |
| Education | $64.54 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,858 |
| Alnylam Pharmaceuticals Inc. Jun 5, 2025 | Travel and Lodging travel to Honolulu, HI · in-kind | $5,858 |
| Alnylam Pharmaceuticals Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,132 |
| Novo Nordisk Inc Nov 8, 2025 | Consulting Fee | $2,998 |
| Novo Nordisk Inc Nov 8, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $36.40 |
| Novo Nordisk Inc Apr 17, 2025 | Education Rivfloza · Rare Disease · in-kind | $32.27 |
| Novo Nordisk Inc Apr 17, 2025 | Education Rivfloza · Rare Disease · in-kind | $32.27 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $77,617 in research payments for these studies, mostly to the institutions running them.
- ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals Inc. - ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals Inc. - BONAPHIDE: A prospective observational study of patients with primary hyperoxaluria type 1 (PHI).
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.